JP2014532074A - ＩＬ７受容体のα鎖に対する抗体‐薬剤候補物質の製造におけるこれらの使用 - Google Patents

ＩＬ７受容体のα鎖に対する抗体‐薬剤候補物質の製造におけるこれらの使用 Download PDF

Info

Publication number
JP2014532074A
JP2014532074A JP2014536177A JP2014536177A JP2014532074A JP 2014532074 A JP2014532074 A JP 2014532074A JP 2014536177 A JP2014536177 A JP 2014536177A JP 2014536177 A JP2014536177 A JP 2014536177A JP 2014532074 A JP2014532074 A JP 2014532074A
Authority
JP
Japan
Prior art keywords
seq
antibody
amino acid
sequence
cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2014536177A
Other languages
English (en)
Japanese (ja)
Other versions
JP2014532074A5 (enExample
Inventor
ブロウアルド ソフィエ
ブロウアルド ソフィエ
ホア マイ レ
ホア マイ レ
マリ カロリネ
マリ カロリネ
ポイリエル ニコラス
ポイリエル ニコラス
ソウリロウ ジャン‐ポール
ソウリロウ ジャン‐ポール
バンホベ ベルナルド
バンホベ ベルナルド
Original Assignee
エフィムネ
インスティテュート ナショナル デ ラ サンテ エト デ ラ レシェルシェ メディカレ
インスティテュート ナショナル デ ラ サンテ エト デ ラ レシェルシェ メディカレ
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by エフィムネ, インスティテュート ナショナル デ ラ サンテ エト デ ラ レシェルシェ メディカレ, インスティテュート ナショナル デ ラ サンテ エト デ ラ レシェルシェ メディカレ filed Critical エフィムネ
Publication of JP2014532074A publication Critical patent/JP2014532074A/ja
Publication of JP2014532074A5 publication Critical patent/JP2014532074A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Endocrinology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Transplantation (AREA)
  • Reproductive Health (AREA)
  • Pulmonology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2014536177A 2011-10-19 2012-10-04 ＩＬ７受容体のα鎖に対する抗体‐薬剤候補物質の製造におけるこれらの使用 Pending JP2014532074A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP11306353.1 2011-10-19
EP11306353.1A EP2583980A1 (en) 2011-10-19 2011-10-19 Antibodies directed against the alpha chain of IL7 receptor - their use for the preparation of drug candidates
PCT/EP2012/069670 WO2013056984A1 (en) 2011-10-19 2012-10-04 Antibodies directed against the alpha chain of il7 receptor - their use for the preparation of drug candidates

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2017106295A Division JP6621778B2 (ja) 2011-10-19 2017-05-30 ＩＬ７受容体のα鎖に対する抗体‐薬剤候補物質の製造におけるこれらの使用

Publications (2)

Publication Number Publication Date
JP2014532074A true JP2014532074A (ja) 2014-12-04
JP2014532074A5 JP2014532074A5 (enExample) 2016-05-19

Family

ID=47018987

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2014536177A Pending JP2014532074A (ja) 2011-10-19 2012-10-04 ＩＬ７受容体のα鎖に対する抗体‐薬剤候補物質の製造におけるこれらの使用
JP2017106295A Active JP6621778B2 (ja) 2011-10-19 2017-05-30 ＩＬ７受容体のα鎖に対する抗体‐薬剤候補物質の製造におけるこれらの使用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2017106295A Active JP6621778B2 (ja) 2011-10-19 2017-05-30 ＩＬ７受容体のα鎖に対する抗体‐薬剤候補物質の製造におけるこれらの使用

Country Status (5)

Country Link
US (1) US9447182B2 (enExample)
EP (3) EP2583980A1 (enExample)
JP (2) JP2014532074A (enExample)
ES (1) ES2854708T3 (enExample)
WO (1) WO2013056984A1 (enExample)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2022518770A (ja) * 2019-01-22 2022-03-16 ブリストル－マイヤーズ スクイブ カンパニー Ｉｌ－７ｒアルファサブユニットに対する抗体及びその使用
WO2025089399A1 (ja) * 2023-10-26 2025-05-01 国立研究開発法人国立がん研究センター インターロイキン７受容体（ｉｌ－７ｒ）に対する抗体および当該抗体を含む抗体薬物コンジュゲート（ａｄｃ）

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2482342B1 (es) * 2012-12-27 2015-07-02 Consejo Superior De Investigaciones Científicas (Csic) TRATAMIENTO TERAPÉUTICO DE LEUCEMIAS LINFOBLÁSTICAS AGUDAS T y B Y LINFOMAS HUMANOS POR INHIBICIÓN DEL RECEPTOR DE INTERLEUQUINA-7 (IL-7R)
EP2955196A1 (en) * 2014-06-10 2015-12-16 Effimune Antibodies directed against CD127
AU2015332151A1 (en) 2014-10-18 2017-04-27 Pfizer Inc. Anti-IL-7R antibody compositions
CA2981098A1 (en) 2015-03-31 2016-10-06 Vhsquared Limited Peptide construct having a protease-cleavable linker
HK1250040A1 (zh) 2015-03-31 2018-11-23 Sorriso Pharmaceuticals, Inc. 多肽
AU2016329034B2 (en) * 2015-09-22 2019-05-23 Pfizer Inc. Method of preparing a therapeutic protein formulation and antibody formulation produced by such a method
WO2017055966A1 (en) 2015-10-01 2017-04-06 Pfizer Inc. Low viscosity antibody compositions
EP3359570A1 (en) 2015-10-07 2018-08-15 The U.S.A. As Represented By The Secretary, Department Of Health And Human Services Il-7r-alpha specific antibodies for treating acute lymphoblastic leukemia
SMT201900460T1 (it) * 2016-02-29 2019-09-09 Ose Immunotherapeutics Anticorpi non antagonisti diretti contro la catena alfa del dominio extracellulare del recettore di il17 e loro uso nel trattamento del cancro
MY190770A (en) 2016-12-09 2022-05-12 Ose Immunotherapeutics Antibodies and polypeptides directed against cd127
AU2018248423A1 (en) 2017-04-04 2019-10-17 Loma Linda University Biologic for the treatment of cancer
WO2019043065A1 (en) * 2017-08-29 2019-03-07 Ose Immunotherapeutics METHOD AND PREPARATION FOR SORTING T EFFECTOR LYMPHOCYTES USING ANTI-CD127 ANTIBODIES FOR CELL THERAPY APPLICATIONS
AU2020294980A1 (en) 2019-06-21 2022-02-17 Sorriso Pharmaceuticals, Inc. Polypeptides
EP3986931A1 (en) 2019-06-21 2022-04-27 Sorriso Pharmaceuticals, Inc. Polypeptides
MX2021015762A (es) 2019-06-21 2022-04-18 Sorriso Pharmaceuticals Inc Composiciones.
CA3250546A1 (en) 2022-05-30 2023-12-07 Ose Immunotherapeutics IL7R MODULATOR ACTIVITY BIOMARKERS
EP4572772A1 (en) 2022-08-17 2025-06-25 Capstan Therapeutics, Inc. Conditioning for in vivo immune cell engineering
EP4455308A1 (en) 2023-04-24 2024-10-30 Les Laboratoires Servier Il-7r gene signatures
US12311033B2 (en) 2023-05-31 2025-05-27 Capstan Therapeutics, Inc. Lipid nanoparticle formulations and compositions
US20250127728A1 (en) 2023-10-05 2025-04-24 Capstan Therapeutics, Inc. Constrained Ionizable Cationic Lipids and Lipid Nanoparticles
WO2025076113A1 (en) 2023-10-05 2025-04-10 Capstan Therapeutics, Inc. Ionizable cationic lipids with conserved spacing and lipid nanoparticles
WO2025098341A1 (en) * 2023-11-10 2025-05-15 Inmagene Biopharmaceuticals (Hangzhou) Co., Ltd. IL-7Ra TARGETING ANTIBODIES AND USES THEREOF
US20250302763A1 (en) 2024-02-22 2025-10-02 Capstan Therapeutics, Inc. Immune engineering amplification
WO2025202213A1 (en) 2024-03-26 2025-10-02 Institut National de la Santé et de la Recherche Médicale Lipid nanoparticle loaded with antitumoral agent and functionnalized to target immosuppressive cells
WO2025217454A2 (en) 2024-04-11 2025-10-16 Capstan Therapeutics, Inc. Ionizable cationic lipids and lipid nanoparticles
WO2025217452A1 (en) 2024-04-11 2025-10-16 Capstan Therapeutics, Inc. Constrained ionizable cationic lipids and lipid nanoparticles

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008144763A2 (en) * 2007-05-21 2008-11-27 Alder Biopharmaceuticals, Inc. Antibodies to il-6 and use thereof
WO2010017468A1 (en) * 2008-08-08 2010-02-11 Glaxo Wellcome Manufacturing Pte Ltd Treatment of autoimmune and inflammatory disease
WO2010138184A2 (en) * 2009-05-27 2010-12-02 Synageva Biopharma Corp. Avian derived antibodies
WO2011094259A2 (en) * 2010-01-28 2011-08-04 Glaxo Group Limited Cd127 binding proteins

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2655392A1 (en) * 2006-05-31 2007-12-06 The Regents Of The University Of California Cd127 expression inversely correlates with foxp3 and suppressive function of cd4+ tregs
WO2010085643A1 (en) * 2009-01-22 2010-07-29 University Of Miami Targeting il-7 signaling as a therapy for multiple sclerosis and other il-7 signaling dependent disorders
US8298535B2 (en) 2010-02-24 2012-10-30 Rinat Neuroscience Corp. Anti-IL-7 receptor antibodies

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008144763A2 (en) * 2007-05-21 2008-11-27 Alder Biopharmaceuticals, Inc. Antibodies to il-6 and use thereof
WO2010017468A1 (en) * 2008-08-08 2010-02-11 Glaxo Wellcome Manufacturing Pte Ltd Treatment of autoimmune and inflammatory disease
WO2010138184A2 (en) * 2009-05-27 2010-12-02 Synageva Biopharma Corp. Avian derived antibodies
WO2011094259A2 (en) * 2010-01-28 2011-08-04 Glaxo Group Limited Cd127 binding proteins

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
CHUNG B. ET AL., BLOOD, vol. 110(8)(2007), JPN6016023148, pages 2803 - 2810, ISSN: 0003342247 *
NIMMERJAHN F. ET AL., CURRENT OPINION IN IMMUNOLOGY, vol. 19(2007), JPN6017001903, pages 239 - 245, ISSN: 0003484953 *
RUDIKOFF S. ET AL., PROC. NATL. ACAD. SCI. USA, vol. vol.79(1982), JPN6017001905, pages 1979 - 1983, ISSN: 0003484954 *

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2022518770A (ja) * 2019-01-22 2022-03-16 ブリストル－マイヤーズ スクイブ カンパニー Ｉｌ－７ｒアルファサブユニットに対する抗体及びその使用
JP7285936B2 (ja) 2019-01-22 2023-06-02 ブリストル－マイヤーズ スクイブ カンパニー Ｉｌ－７ｒアルファサブユニットに対する抗体及びその使用
JP2023103456A (ja) * 2019-01-22 2023-07-26 ブリストル－マイヤーズ スクイブ カンパニー Ｉｌ－７ｒアルファサブユニットに対する抗体及びその使用
JP7514363B2 (ja) 2019-01-22 2024-07-10 ブリストル－マイヤーズ スクイブ カンパニー Ｉｌ－７ｒアルファサブユニットに対する抗体及びその使用
JP2024129090A (ja) * 2019-01-22 2024-09-26 ブリストル－マイヤーズ スクイブ カンパニー Ｉｌ－７ｒアルファサブユニットに対する抗体及びその使用
WO2025089399A1 (ja) * 2023-10-26 2025-05-01 国立研究開発法人国立がん研究センター インターロイキン７受容体（ｉｌ－７ｒ）に対する抗体および当該抗体を含む抗体薬物コンジュゲート（ａｄｃ）

Also Published As

Publication number Publication date
JP2017184753A (ja) 2017-10-12
ES2854708T3 (es) 2021-09-22
JP6621778B2 (ja) 2019-12-18
EP2768860A1 (en) 2014-08-27
WO2013056984A1 (en) 2013-04-25
EP3299392B1 (en) 2020-11-18
EP2583980A1 (en) 2013-04-24
US9447182B2 (en) 2016-09-20
EP3299392A1 (en) 2018-03-28
US20140308281A1 (en) 2014-10-16

Similar Documents

Publication Publication Date Title
JP6621778B2 (ja) ＩＬ７受容体のα鎖に対する抗体‐薬剤候補物質の製造におけるこれらの使用
CN110156892B (zh) 抗pd-l1抗体及其作为治疗剂及诊断剂的用途
JP6986965B2 (ja) 抗ｐｄ−１抗体
JP6909153B2 (ja) 抗ｐｄ−ｌ１抗体
US11525005B2 (en) Anti-CD40 antibody, antigen binding fragment thereof and medical use thereof
EP3423496B1 (en) Non-antagonistic antibodies directed against the alpha chain of the il7 receptor extracellular domain and use thereof in cancer treatment
CA3207791A1 (en) Anti-cd112r antibody and use thereof
US20240228649A9 (en) Crtam antibodies and methods of treating cancer
CN114008077B (zh) 抗体和使用方法
EP3524624A1 (en) Anti-cd27 antibody, antigen-binding fragment thereof, and medical use of same
CN114573703A (zh) 一种t细胞衔接器治疗剂的开发和应用
US20240269276A1 (en) Specific binding protein targeting pd-l1 and cd73
TWI833227B (zh) 靶向pd-l1和cd73的特異性結合蛋白及其應用
RU2779128C2 (ru) Антитело к cd40, его антигенсвязывающий фрагмент и его медицинское применение
HK40005909B (en) Anti-pd-l1 antibodies and their use as therapeutics and diagnostics
OA20097A (en) Antibodies directed against CD127.

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20150414

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20150904

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20150904

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160322

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20160621

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20160916

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A712

Effective date: 20161004

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20161004

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20161104

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20161220

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20170131